Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Paratek Pharmaceuticals Inc    PRTK

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
24.2(c) 23.3(c) 23.55(c) 24.1(c) 23.75(c) Last
972 157 750 938 507 662 834 245 693 096 Volume
+7.56% -3.72% +1.07% +2.34% -1.45% Change
More quotes
Financials ($)
Sales 2017 8,00 M
EBIT 2017 -99,6 M
Net income 2017 -103 M
Finance 2017 8,17 M
Yield 2017 -
Sales 2018 16,3 M
EBIT 2018 -95,2 M
Net income 2018 -98,2 M
Debt 2018 7,15 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 80,5x
EV / Sales2018 40,4x
Capitalization 653 M
More Financials
Company
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry.Its products include Omadacycline and Sarecycline.The company was founded in February 2001 and is... 
More about the company
Surperformance© ratings of Paratek Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on PARATEK PHARMACEUTICALS IN
06/22 PARATEK PHARMACEUTICALS : Researchers Submit Patent Application, "Methods for Sy..
06/16 PARATEK PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Submi..
06/14 Paratek Pharmaceuticals, Inc. to Participate in JMP Securities Life Science C..
06/05 PARATEK PHARMACEUTICALS : New Microbiology Data Reinforce Activity of Parateks O..
06/03 PARATEK PHARMACEUTICALS : New Microbiology Data Reinforce Activity of Paratek&rs..
06/03 New Microbiology Data Reinforce Activity of Paratek’s Omadacycline Agai..
05/25 PARATEK PHARMACEUTICALS : to Present New Data from Omadacycline Development Prog..
05/24 Paratek Pharmaceuticals to Present New Data from Omadacycline Development Pro..
05/18 PARATEK PHARMACEUTICALS : Announces Completion of Enrollment for Oral-only Omada..
05/09 PARATEK PHARMACEUTICALS : Announces Completion of Enrollment for Oral-only Omada..
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/23Paratek Pharmaceuticals’ $PRTK Overweight Rating Reiterated at Cantor Fitzger.. 
06/23Paratek Pharmaceuticals's overweight rating reiterated at Cantor Fitzgerald. .. 
06/22$PRTK initiated at Overweight at Cantor. PT $50
1
06/22Paratek Pharmaceuticals, Inc. $PRTK CFO Douglas W. Pagan Sells 4,595 Shares  
06/20Paratek Pharmaceuticals, Inc. $PRTK Given Average Recommendation of “Buy” by .. 
More tweets
Qtime:10
News from SeekingAlpha
06/22 Premarket analyst action - healthcare
06/19 FDA OKs new antibiotic to fight ABSSSI
05/22 PARATEK PHARMACEUTICALS : The 1 Antibiotic Stock To Buy Now
05/14 Tracking Seth Klarman's Baupost Group Holdings - Q1 2017 Update
05/07 Paratek Pharmaceuticals' (PRTK) CEO Michael Bigham on Q1 2017 Results - Earni..
Advertisement
Chart PARATEK PHARMACEUTICALS IN
Duration : Period :
Paratek Pharmaceuticals In Technical Analysis Chart | PRTK | US6993743029 | 4-Traders
Full-screen chart
Technical analysis trends PARATEK PHARMACEU...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 42,6 $
Spread / Average Target 79%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael F. Bigham Chairman & Chief Executive Officer
Evan Loh President, COO, Director & CMO
Douglas W. Pagán Chief Financial & Accounting Officer
Paul McGovern Vice President-Clinical & Medical Affairs
Thomas John Dietz Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PARATEK PHARMACEUTICAL..54.22%653
AMGEN17.98%126 856
CELGENE CORPORATION16.03%104 873
GILEAD SCIENCES-1.52%92 150
REGENERON PHARMACEUTIC..43.43%54 987
VERTEX PHARMACEUTICALS83.97%33 251
More Results